Brief: Biophytis Announces Signature Of Master Service Agreement With Intsel Chimos
01/03/2023 23:03
March 1 (Reuters) - Biophytis SA ALBPS.PA :
* BIOPHYTIS ANNOUNCES THE SIGNATURE OF A MASTER SERVICE
AGREEMENT
WITH INTSEL CHIMOS, A PHARMACEUTICAL COMPANY THAT WILL OPERATE
SARCONEOS (BIO101) IN FRANCE FOR THE TREATMENT OF SEVERE FORMS
OF COVID-1
* BIOPHYTIS SA - APPLICATION REQUEST AIMS TO ALLOW TREATMENT
WITH
SARCONEOS FOR PATIENTS WITH SEVERE FORMS OF COVID-19 AS OF
SECOND HALF OF 2023
Source text for Eikon: ID:nEQ5NscZGa
Further company coverage: ALBPS.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon